Technical Data
Carcinoembryonic Antigen (CEA, CD66e)
Carcinoembryonic antigen (CEA), which is synthesized during development in the fetal gut, and is re-expressed in increased amounts in intestinal carcinomas and several other tumors. Anti-CEA is reportedly useful in identifying the origin of various metastatic adenocarcinomas and in distinguishing pulmonary adenocarcinomas (60-70% are CEA+) from pleural mesotheliomas (rarely or weakly CEA+).

Suitable for use in Immunoprecipitation, Western Blot and Immunohistochemistry. Other applications not tested.

Recommended Dilutions:
Immunoprecipitation (Native and denatured): 10ul/mg protein lysate. Use Protein A.
Western Blot: 1:200 for 2 hours at RT
Immunohistochemistry (Formalin/paraffin): 1:250-1:500. Incubate for 20 minutes at RT. No special pretreatment is required for the immunohistochemical staining of formalin/paraffin tissue.
Optimal dilution determined by the researcher.

Recommended Positive Control:
LS174T cells or colon carcinoma

Storage and Stability:
May be stored at 4░C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20░C. Aliquots are stable for 12 months after receipt. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
PabIgGHighly Purified
500ul-20░CBlue IceHumanRabbit
Not Determined
Human CEA isolated from hepatic metastasis of colon adenocarcinoma. Cellular Localization: Cytoplasmic and lumenal membrane. MW of Antigen: 180kD.
Purified by ammonium sulfate precipitation, followed by ion-exchange chromatography and appropriate solid-phase absorption
Supplied as a liquid in PBS, pH 7.4, 0.2% BSA, 0.09% sodium azide.
Recognizes human CEA and CEA-like proteins such as non-specific crossreacting antigen (NCA), NCA2, and biliary glycoprotein (BGP1). Has been absorbed with plasma proteins and blood group antigens A and B. Species Crossreactivity: mouse. Weakly reacts with rat. Does not react with canine.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
Whited, A. M. et al., (2012) Bionanoscience, DOI: 10.1007/s12668-012-0049-2. 1. Nap, M., et al., Int. J. Biol. Markers 7: 148-153 (1992). 2. Bergeron, A., et al., Cancer Res. 56: 908-915 (1996). 3. Lee, J.S., et al, Acta. Cytologica 40: 631-636 (1996). 4. Nakamura, T., et al., Cancer 77: 1741-1746 (1996). 5.áPrall, F., et al., Journal of Histochemistry and Cytochemistry 44: 35-41 (1996). 6. Sundblad, A., et al., Human Pathology 27: 297-301 (1996). 7. Webb, A., et al., European Journal of Cancer 32A: 63-68 (1996). 8. Moyana, T.N., et al., Cancer 75: 2836-2843 (1995). 9. Parkkila, S., et al., European Journal of Nuclear Medicine 22: 1064-1068 (1995). 10. Rosner, D., et al., Cancer Investigation 13: 573-582 (1995). 11. Tokunaga, N., et al., Diseases of the Colon and Rectum 38: 842-847 (1995).